Published in Drug Law Weekly, February 20th, 2007
The District Court in The Hague held that Conor's CoStar paclitaxel stent infringes a key claim of the Dutch version of an important Angiotech European stent patent, and that Conor is therefore immediately enjoined from selling CoStar in the Netherlands.
"This is a significant victory in a key area of our intellectual property," said William L. Hunter, president and CEO of Angiotech. "Conor's attempt to design around our patented technology has failed. Not only did the Court uphold...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.